Kornimate/medical-research-clean huggingface dataset:
patient position and invasive urodynamic study results in males

Conditions: Lower Urinary Tract Symptoms; Diagnosis

Summary: the goal of this study is to learn whether the change or patient position might effect the results of invasive urodynamic study in males.

males will be randomised as group 1 and group 2. in group 1, invasive urodynamic study will be performed first in sitting then repeated in standing position. in group 2, invasive urodynamic study will be performed first in standing then repeated in sitting position. results will be compared.

Eligibility criteria:
inclusion criteria: * males over 18 years old and capable of standing during test exclusion criteria: * patients not able to stand up during the test
observational study on patients with baclofen treatment for alcohol-dependence in france

Conditions: Alcohol Drinking; Cirrhosis; Alcohol Withdrawal

Summary: baclofen is an agonist of the amino-butyricum b (gaba-b) receptor used for a long time in neurology to treat spastic contracture. several clinical studies have suggested its efficacy in the treatment of alcohol-dependence in low, even in case of cirrhosis and high dose. french drug authority has authorized its use in 2012 whereas the l'european association for the study of the liver recommends to perform additional studies on this indication. the goal of this observational study is to evaluate the use of baclofen for alcohol-dependence in real life care as well its efficacy.

numerous centers of the french research group of the national association of the hepatologists and gastroenterologists from general hospitals (angh) will be part of this study. patients treated with baclofen for alcohol -dependence will be enroll prospectively from 2014 and retrospectively if they were treated between 2012 and 2014. the reported alcohol consumption, biological markers of excessive alcohol, initial and usual baclofen dosage, blood balofen dosage as well as clinical data will be collected.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old * patient treated with baclofen therapy after 2012 for alcoholo-dependance exclusion criteria: * baclofen therapy before 2012 * patient who refuse to participate

Keywords: baclofen alcohol withdrawal
t-macs decision aid: a randomized, controlled point of care trial

Conditions: Heart Attack; Chest Pain; Acute Coronary Syndrome

Summary: the aim of the study is to establish whether the safety of the t-macs decision aid to immediately 'rule out' acute coronary syndromes with one blood sample for the cardiac damage marker troponin, is non-inferior to an approach requiring serial troponin sampling over three hours.

we will conduct a randomized, controlled point of care trial embedded in routine practice. we will ask clinicians to obtain written informed consent during the course of their clinical duties. patients who have suspected cardiac chest pain, who are identified as being at very low risk by the t-macs algorithm, will be invited to participate. patients will then be randomly allocated to be advised that they can be discharged immediately (so long as the doctor and patient have no other concerns; this is the originally intended use of t-macs; intervention arm) or to receive a second blood test after 3 hours (current practice; control arm). participants will then be followed up by electronic record review after 30 days and 12 months. other than the difference in the requirement for a second blood test, participants will not notice any change to their care. the accelerated pathway (involving a single blood test) has been shown to be safe in observational research involving over 5,000 patients. all of the data that are collected are the same of those that are collected in routine care, and they will be anonymised for analysis.

Eligibility criteria:
inclusion criteria: * \>18 years of age * presents to the emergency department with pain, discomfort or pressure in the chest, epigastrium, neck, jaw, or upper limb without an apparent non-cardiac source which the treating physician believes warrants investigation for possible acute coronary syndrome * the patient is identified as being at 'very low risk' by the t-macs decision aid following a single hs-ctn test at the time of arrival in the emergency department exclusion criteria: * no capacity to provide informed consent * inability to communicate in english language if translation services are unavailable * patient is a prisoner * no nhs number (precluding electronic follow up)

Keywords: t-macs
malaria control : improving access to prevention, diagnostic and care for vulnerable rural communities

Conditions: Malaria

Summary: in the react 2 project, a consortium proposes to study in burkina faso and côte d'ivoire, the impact of a public health intervention in rural communities in order to improve access to malaria therapeutic and preventive arsenal for vulnerable populations (i.e. children, adolescents and pregnant women). the intervention relies on the implementation of mobile health workers to support community health workers.


Eligibility criteria:
inclusion criteria: * global population exclusion criteria: * absence of informed consent
study of iw-1701, a stimulator of soluble guanylate cyclase (sgc), in patients with type i or ii achalasia

Conditions: Achalasia

Summary: the objectives of this study are as follows: in participants with primary type i or ii achalasia, following a single 5-mg dose of olinciguat (iw-1701), * to assess the safety and tolerability * to determine the effects on measures of esophageal function by high-resolution impedance manometry (hrim) * to determine the pharmacokinetic (pk) parameters


Eligibility criteria:
key inclusion criteria: * patient has a diagnosis of primary type i or ii achalasia. * patient has no contraindications to the performance of the baseline and postdose hrim procedures per investigator discretion. key exclusion criteria: * patient has had any prior esophageal, periesophageal, or gastric surgery, or treatment with sclerosing agent. * more than 1 pneumatic dilation procedure to a diameter of \> 2 cm in their lifetime. * pneumatic dilation procedure to a diameter of \> 2 cm within 1 year prior to randomization. prior bougie dilation(s) or pneumatic dilation(s) ≤ 2 cm are allowed. * prior esophageal injection of botulinum toxin (botox) within 6 months prior to randomization or more than 2 esophageal botox injection procedures in their lifetime. * patients with malignant or premalignant esophageal lesions. * patient has taken any drug that can affect gastrointestinal (gi) motility in the 72 hours before check-in through discharge from the clinic. other inclusion and exclusion criteria specified in the protocol.
health trial - healthy adult evaluation of ivermectin bioequivalence: infant versus standard formulation

Conditions: Scabies

Summary: this is a clinical trial to compare two formulations of the drug ivermectin: the standard 3mg tablet formulation versus a newly developed infant formula preparation. the goal of the trial is to determine if the new formulation functions in the same way, tastes the same and causes no new side effects. the trial will involve 52 participants who will be healthy adult volunteers. the participants will receive both formulations - the order they receive each formulation will be assigned randomly (similar to the toss of a coin).

randomised open-label cross-over trial of 52 healthy adult volunteers comparing two ivermectin formulations: the standard tablet formulation, and a newly developed infant formula preparation. participants will be randomised to receive one of these two formulations at the start of the trial and after a 21 day wash out period will be given the alternative formulation. blood samples will be taken to determine serum drug concentrations. the bioequivalence, tolerability and drug-related adverse effects will be evaluated.

Eligibility criteria:
inclusion criteria: * adult aged over 18 years up to 55 years; and * body mass index of 18.0 - 32.0 kg/m2 with body weight ≥ 50.0 kg; and * medically healthy, determined by medical history, physical examination, no clinically significant abnormalities on baseline blood tests, vital signs (blood pressure, oxygen saturation and heart rate) as deemed by the study doctor; and * females must be non-pregnant, non-lactating or postmenopausal for at least 1 year or surgically sterile for at least 6 months prior to dosing; and * sexually active, non-pregnant female participants will be required to use an effective form of contraception from 28 days prior to study until end of study; and * males must not have a pregnant partner and must agree to use condoms as a method of contraception from the time of signing informed consent until end of the study; and * must be willing and able to read, understand, and sign the participant information and consent form. willing to comply with all study requirements, including the inpatient period and outpatient visits for the duration of the study; and * good venous access on at least one arm as assessed by study staff. exclusion criteria: * history of any clinically important cardiac, endocrinologic, haematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major disease, as determined by the study doctor; or * known allergy to ivermectin or taking a drug that interacts with ivermectin via the p-glycoprotein transport system (e.g. amiodarone, carvedilol, clarithromycin, clotrimazole); or * currently taking warfarin; or * known lactose intolerance or cow's protein intolerance; or * known elective surgery scheduled within the next 3 months; or * inability to comply with the study protocol.

Keywords: ivermectin
safety and effectiveness of the pxl-platinum 330 system

Conditions: Corneal Ectasia; Keratoconus; Pellucid Marginal Corneal Degeneration

Summary: to evaluate the safety and effectiveness of the pxl platinum 330 system for performing corneal cross-linking (cxl) for the treatment of ectatic disorders.

patients with progressive keratoconus, pellucid marginal degeneration, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the peschke pxl-330 system using pulsed, accelerated energy delivery. patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, intraocular pressure, and pachymetry.

Eligibility criteria:
inclusion criteria: 1. diagnosis of keratoconus, forme fruste keratoconus, post-lasik ectasia, pellucid marginal degeneration, forme fruste pellucid marginal degeneration, history of radial keratotomy with fluctuating vision, terrien's marginal degeneration. 2. must have provided informed consent, documented it in writing, and have been given a copy of the signed informed consent form. 3. must be willing and able to return for scheduled treatment and follow-up examinations for the duration of the study. 4. must be at least 8 years of age. 5. non-consenting/impaired individuals with a lar's signature exclusion criteria: 1. corneal thickness \< 300 microns measured by ultrasound or pentacam. 2. contraindications or sensitivities to any study medications or their components. 3. pregnancy or breastfeeding. 4. any history of herpes simplex corneal disease in an eye to be treated. 5. nystagmus or any other condition that would, in the judgement of the investigator, prevent a steady gaze during the treatment. 6. inability to cooperate with diagnostic tests. 7. current enrollment in another ophthalmic clinical trial.
a study of ly2623091 in participants with high blood pressure

Conditions: Primary Hypertension

Summary: the main purpose of this study is to evaluate the safety and effectiveness of the study drug known as ly2623091 in participants with high blood pressure.


Eligibility criteria:
inclusion criteria: * have a history of hypertension. * if participants are naïve to treatment of hypertension, or have not been treated with any antihypertensive medications within the 30 days immediately prior to screening: * have seated systolic (sbp) of ≥140 and \<170 millimeters of mercury (mmhg) at screening and at the end of the lead-in period. * if participants are currently being treated for hypertension: * are taking a stable dose of 1 or 2 antihypertensive medications for at least the previous 30 days. a combination antihypertensive medication from 2 classes is considered as 2 antihypertensive medications. * are willing to discontinue the antihypertensive medications during the study. * have seated sbp of ≥140 and \<170 mmhg at the end of the lead-in period. * have a body mass index (bmi) ≥18.5 and \<40 kilograms/m\^2. exclusion criteria: * have a history of severe hypertension (defined as sbp ≥180 mmhg and/or diastolic (dbp) ≥120 mmhg), secondary hypertension, symptomatic postural hypotension, or hospitalization due to hypertension. * have sbp ≥180 mmhg and/or dbp ≥110 mmhg at screening, lead-in period, or randomization. * have a history of hospitalization due to hyperkalemia, or history of drug discontinuation due to elevated serum potassium levels. * have a serum potassium ≤3.5 or \>5.0 millimoles per liter (mmol/l). * have an estimated glomerular filtration rate (egfr) \<50 milliliters/minute/1.73 m\^2.
effect of dynamic cupping & myofascial release on pain, rom and performance in athletes with low back pain

Conditions: Low Back Pain; Myofascial Pain; Back Strain

Summary: data will be collected at pakistan sports board lahore. study design will be randomized clinical trial. sample size is 28. population will be divided into two groups by convinient sampling technique. group a willl be treated with dynamic cupping and group b will be treated with soft tissue myofascial release. inclinometer, back pain functional scale, functional mobility scale and numerc pain rating scale will be used to generate the outcomes of study.

the objective of this study is to compare the effects of dynamic cupping versus myofascial release on pain, range of motion and function in athletes with non-specific low back pain. tools to be used in this study will be : inclinometer: an inclinometer is a sensor used to measure the magnitude of the inclination angle or deformation of any structure . back pain functional scale: a subjective scale used to measure the patient's physical function after low back pain. fms: the functional mobility scale (fms) has been constructed to classify functional mobility. numeric pain ratig scale: the numeric rating scale (nrs) is a pain the screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable". the study will be collected from sports related persons at pakistan sports board lahore. first, a consent form will be filled the person and then the data will be recorded through our questionaire on day 1 and then after 6 weeks of treatment. group a will be treated with dynamic cupping and group b will be treated with myofascial release. group a: will be an interventional group and it will be treated by using dynamic cupping. heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and cup will be placed,a vacuum will be created by using a vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes. group b : will be a control group and it will be treated by soft tissue myofascial release. heating pad will be applied for 10 minutes as a base treatment, and petroleum jelly will be applied to the area followed by soft tissue myofascial release technique for 5 minutes either crisscross, along the fiber or in figure of 8.

Eligibility criteria:
inclusion criteria: * both male and female * 18-35years(1) * low backpain * nprs (3 to 10 cut of value) * must be a sports related persons. exclusion criteria: * systemic illness. (diabetes mellitus,tuberculosis, arthritis, scoliosis) * history of fracture in last 6 months * stayed out of sports from last 6 months * history of disc buldge and another structural problem.

Keywords: athletic performance low back pain myofascial release range of motion
augmented reality in oral surgery

Conditions: Impacted Tooth

Summary: a digital workflow was used to assist the oral surgeon in pre-orthodontic exposure of a vestibular impacted canine using augmented reality. through software for the object recognition and tracking, the researchers expand reality with cone beam computer tomography digital contents to optimize the outcome of surgery. the real-time video frames of the operating field aligned with the three-dimension file of the impacted tooth, were used as a guide to evaluate the surgical access to perform a minimally invasive flap and osteotomy.

this study evaluate an ar-assisted approach for surgical exposure of a maxillary impacted canine. the usual protocol is the following: * maxillary arches were scanned, and their occlusal relationship was registered using an optical intraoral scanner.the file was exported in polygon file format (ply) * using open-source cad software, the part of the upper arch was selected from the first premolar to the other first premolars the teeth, the incisal edges and the cusps of the anterior sector were the anatomical markers required to match the patient's mouth and perform the object recognition.to this file that corresponded faithfully to reality we added the digital information required, that is, the position of the impacted crown of the canine * from the maxillary cbct, dicom files were imported in open-source medical software for segmentation and exportation of an stl file of the area of interest * two 3d files obtained were imported into a cad-cam design software for superimposition. 3d file consisting of the intraoral scan plus the endosseous position of the crown of the impacted canine was exported * a full hd video camera was positioned in front of the patient's mouth, connected via an hdmi cable to a laptop * the ar software was then started, and the video camera was associated as an input source the software recognizes edges of files in images transmitted from the camera and overlap the object to the video images.

Eligibility criteria:
inclusion criteria: * presence of an impacted tooth in aesthetic area * good health according to the system of the american society of anesthesiology * no general medical contraindication for oral surgery * good periodontal health exclusion criteria: * smoking more than 15 cigarettes a day • untreated periodontitis * pregnancy * acute infections

Keywords: augmented reality oral surgery computer guided surgery computer assisted surgery
safety and efficacy of ibi188 with azacitidine in subjects with newly diagnosed higher risk mds

Conditions: Myelodysplastic Syndromes

Summary: the study is to evaluate safety and efficacy of ibi188 in combination with azacitidine (aza) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome


Eligibility criteria:
inclusion criteria: 1. mds subjects with higher risk; 2. age ≥ 18 years old; 3. eastern cooperative oncology group score of 0\~1; 4. not suitable for or refuse to receive hsct; 5. newly diagnosed mds subjects; 6. adequate organ function; 7. subjects should take effective contraceptive measures 8. must sign the informed consent form (icf), and be able to follow all study procedures. exclusion criteria: 1. subject who has transformed from mds to aml. 2. therapy-related mds (t-mds), myeloproliferative neoplasm (mpn)- transformed mds,mds/mpn. 3. mds subjects with lower risk. 4. subjects who have received chemotherapy. 5. prior exposure to any anti-cd47 or anti-sirpα agents. 6. subjects participating in another interventional clinical study.

Keywords: mds
sleep apnea in type 1 diabetes

Conditions: Type 1 Diabetes, Sleep Apnea Syndrome

Summary: sleep apnea syndrome is strongly associated to type 2 diabet, partly and this is partly due to obesity. treatment of sleep apnea may improve hypertension, cardiovascular risk and in some studies diabetes status. few data are available for type 1 diabetes but suggest that the prevalence of sleep apnea syndrome may be high. we plan to compare the prevalence of sleep apnea syndrome assessed by polysomnography in a sample of type 1 diabetic patients and a control group matched by age, gender and body mass index. the secondary objective is to determine if the presence of an autonomic neuropathy or poorly controlled diabetes (assessed by glycosylated haemoglobin) may or not contribute to the presence of sleep apnea in the diabetic group.

diagnostic protocol designed to evaluate if if sleep apnea syndrome is more frequent in type 1 diabetes than in general population and therefore deserves to be more systematically suspected and actively diagnosed in this patients. sleep apnea syndrome is a heavy burden as a matter of quality of life: it is responsible for fatigue, diurnal sleepiness, cognitive impairment, poor and /or non restorative sleep, morning headaches, depressive mood...adequate treatment provides a rapid and, most of the time, complete relief of these symptoms. on an other hand, sleep apnea is and independent risk factor for cardiovascular mortality and morbidity in young and middle aged subjects, also reversed by treatment. it might be therefore important for type 1 diabetic patients who have already an increased cardiovascular risk to be properly diagnosed for sleep apnea. a systematic screening for sleep apnea is already recommended for patients with type 2 diabetes by experts. a secondary objective is to determine if the presence of a sleep apnea syndrome in type 1 diabetic patients is associated to an autonomic neuropathy, a poor glycemic control , a poorer quality of life , a poorer quality of sleep, more severe cardiovascular consequences and biological impairment.

Eligibility criteria:
inclusion criteria: * 99 type 1 diabetic patients * man or woman aged 18 to 60 years * diagnosed since at least a year * having signed a consent * with in a national insurance scheme * and 46 healthy volunteers matched by age , gender and body mass index * man or woman aged 18 to 60 years * having signed a consent * with in a national insurance scheme exclusion criteria: for both * sleep apnea syndrome already known * acute respiratory or cardiovascular disease * impairment of consciousness * sepsis * cirrhosis * hypnotic, opiate or psychotropic drug treatment 2 weeks ago * pregnant or breast-feeding woman * do not speak french * benefiting from a legal protective measure * diabet 1 or 2 just for volunteers people

Keywords: type 1 diabetes, sleep apnea, polysomnography, autonomic neuropathy, intima media thickness